MARKET

UMRX

UMRX

Unum Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.940
+0.080
+2.80%
Closed 16:00 09/18 EDT
OPEN
2.860
PREV CLOSE
2.860
HIGH
3.050
LOW
2.780
VOLUME
787.98K
TURNOVER
--
52 WEEK HIGH
3.720
52 WEEK LOW
0.2950
MARKET CAP
112.49M
P/E (TTM)
-3.9002
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AMRN, VXRT, HOME and GOGO among midday movers
Gainers: Corcept Therapeutics (CORT) +35%.Vera Bradley (VRA) +29%.NanoViricides (NNVC) +27%.Gogo (GOGO) +25%.TSR (TSRI) +24%.Flying Eagle Acquisition (FEAC) +23%.SmileDirectClub (SDC) +19%.Vaxart (VXRT) +18%.Clearfield (CLFD) +16%.Lazydays (LAZY) +15%.Losers: Amarin (AMRN) -28%.At Home Group (HOME) -26%.Jiayin (JFIN) -24%.ADiTx Therapeutics (ADTX) -18%.GSX
Seekingalpha · 09/02 16:43
Unum Therapeutics' BOXR CAR-T platform and products rights acquired by SOTIO
Unum Therapeutics' ([[UMRX]] -0.3%) BOXR cell therapy platform and BOXR lead programs, to develop novel T cell therapies for the treatment of solid tumors, were acquired by SOTIO, a clinical stage
Seekingalpha · 08/31 14:12
SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics
* SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts * Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies * Lead program expected to initiate
GlobeNewswire · 08/31 12:30
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology To SOTIO For $8.1M And Up To $3.4M Of Milestone Payments
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO CAMBRIDGE, Mass., Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing
Benzinga · 08/31 11:35
Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?
Is (UMRX) Outperforming Other Medical Stocks This Year?
Zacks · 08/25 16:30
Venrock Healthcare Capital Partners acquires 0.451M shares of Unum Therapeutics
Venrock Healthcare Capital Partners discloses the purchase 0.451M shares of Unum Therapeutics (UMRX) between Aug. 14 and Aug. 18 at average price of $2.52/share.Shares +9% premarket.
Seekingalpha · 08/19 12:50
TGT, NAK among premarket gainers
Momenta Pharmaceuticals (MNTA) +69% on J&J acquisition.Hudson (HUD) +49% on take over offer of $7.70/share from its controlling shareholder.LightInTheBox Holding (LITB) +38% on Q2 results.Teligent (TLGT) +36% on Q2 results.Immunovant (IMVT) +20%.SilverSun Technologies (SSNT)
Seekingalpha · 08/19 12:12
Unum Therapeutics shares are trading lower after the company reported Q2 earnings results.
Benzinga · 08/12 14:58
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average UMRX stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 10.97M
% Owned: 28.68%
Shares Outstanding: 38.26M
TypeInstitutionsShares
Increased
4
1.30M
New
7
-116.73K
Decreased
8
180.31K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
President/Chief Executive Officer/Director
Charles Wilson
Chief Financial Officer/Vice President - Finance/Controller
John Green
Other
Jessica Sachs
Director
Chris Cain
Independent Director
Jorn Aldag
Director
Peter Harwin
Independent Director
Karen Ferrante
Independent Director
Arlene Morris
Independent Director
Matthew Ros
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average UMRX stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About UMRX
Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Unum Therapeutics Inc stock information, including NASDAQ:UMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UMRX stock methods without spending real money on the virtual paper trading platform.